Skip to main content
. 2020 Apr 13;31(3):e61. doi: 10.3802/jgo.2020.31.e61

Fig. 1. Study schema.

Fig. 1

CR, complete response; OS, overall survival; PD, progressive disease; PET/CT, positron emission tomography–computed tomography; PFI, progression-free interval; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PR, partial response; SCR, secondary cytoreductive surgery; SD, stable disease; SGOG, Shanghai Gynecologic Oncology Group; TFI, treatment-free interval; QoL, quality of life.